Novartis Says Canakinumab Didn't Meet Primary Endpoint in Phase 3 Trial for Lung Cancer Treatment
March 09 2021 - 1:47AM
Dow Jones News
By Pietro Lombardi
Novartis AG said Tuesday that a Phase 3 trial evaluating the use
of canakinumab to treat lung cancer didn't meet its primary
endpoint of overall survival.
The Swiss pharmaceutical group said that the canopy-2 trial was
evaluating the use of canakinumab, an inhibitor of
interleukin-1beta, in combination with the chemotherapy agent
docetaxel. The trial involved 237 adults with advanced or
metastatic nonsmall cell lung cancer whose cancer progressed while
on or after previous treatments.
The company said the canakinumab development program continues,
with results from a Phase 3 trial expected by the end of the
year.
Write to Pietro Lombardi at pietro.lombardi@wsj.com;
@pietrolombard10
(END) Dow Jones Newswires
March 09, 2021 01:32 ET (06:32 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Sep 2023 to Sep 2024
